NCT01272856View on ClinicalTrials.gov

Study on the Safety of Abatacept in Relapsing Polychondritis

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Relapsing Polychondritis
Interventions
DRUG

Abatacept

125 mg pre-filled syringe for sub-q injection weekly.

Trial Locations (1)

98101

Virginia Mason Medical Center, Seattle

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Benaroya Research Institute

OTHER